CAS 1334513-10-8: N-[[P(S),2′R]-2′-Deoxy-2′-fluoro-2′-methyl-P-phenyl-5′-cytidylyl]-L-alanine 1-methylethyl ester

Sofosbuvir impurity J is a chemical impurity that arises during the synthesis of Sofosbuvir, an antiviral medication primarily used in the treatment of hepatitis C. This impurity is a byproduct produced during the manufacturing process of Sofosbuvir, originating from its chemical synthesis pathway. The analysis of Sofosbuvir impurity J is crucial for ensuring the purity, efficacy, and safety of the final pharmaceutical product. The presence and quantification of this impurity are typically assessed using sophisticated analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry. The identification of such impurities is critical in regulatory compliance and optimizing the synthesis routes. The study of Sofosbuvir impurity J, as with other impurities, aids in understanding the complete impurity profile of the medication, which is essential for maintaining the stringent quality control standards required for pharmaceuticals. This, in turn, supports the development of more effective and safer antiviral therapies by providing insights into the chemical stability and degradation pathways of the active pharmaceutical ingredient during its lifecycle.

Sofosbuvir impurity J is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.